Incyte's CEO Presents at Morgan Stanley Healthcare Conference (Transcript) Seeking Alpha It was originally put into the clinic for transplant rejection because the target JAK3 is very important for a T-cell proliferation, T-cell activation. We don't hit JAK3, and yet our efficacy is at least as good, so you don't need JAK3 to get the ... |
